Evidence map›Paper›PMID 25584121›Full record

ArticleThe Pan African medical journal2014

Phenotypic and genetic characterization of Vibrio cholerae O1 isolated from various regions of Kenya between 2007 and 2010.

Njeru Mercy, Ahmed Abade Mohamed, Ng'ang'a Zipporah, Goutam Chowdhury, Gururaja Perumal Pazhani, Thandavarayan Ramamurthy, Hamadi I Boga, Samuel M Kariuki, Oundo Joseph

Open access · goldAbstract read
In one paragraph

Article in The Pan African medical journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Resistance ofFrontiers in pharmacology · 2023
    Review
  8. Article
  9. Characterisation ofThe Pan African medical journal · 2020
    Article
  10. Review
  11. Antimicrobial resistance ofAfrican journal of laboratory medicine · 2018
    Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Njeru MercyField Epidemiology and Laboratory Training Program, Kenya Ministry of Public Health and sanitation, Nairobi, Kenya.
Ahmed Abade MohamedField Epidemiology and Laboratory Training Program, Tanzania.
Ng'ang'a ZipporahJomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
Goutam ChowdhuryNational Institute for Cholera and Enteric Diseases (NICED), Kolkata, India.
Gururaja Perumal PazhaniNational Institute for Cholera and Enteric Diseases (NICED), Kolkata, India.
Thandavarayan RamamurthyNational Institute for Cholera and Enteric Diseases (NICED), Kolkata, India.
Hamadi I BogaJomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
Samuel M KariukiKenya Medical Research Institute, Kenya.
Oundo JosephCentre for Disease Control (CDC), Nairobi, Kenya.
National Institute of Cholera and Enteric Diseases · INJomo Kenyatta University of Agriculture and Technology · KECenters for Disease Control and Prevention · KEKenya Medical Research Institute · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCholera, a disease caused by Vibrio cholerae O1 and O139 remains an important public health problem globally. In the last decade, Kenya has experienced a steady increase of cholera cases. In 2009 alone, 11,769 cases were reported to the Ministry of Public Health and Sanitation. This study sought to describe the phenotypic characteristics of the isolated V. cholerae isolates.

methodsThis was a laboratory based cross-sectional study that involved isolates from different cholera outbreaks. Seventy six Vibrio cholerae O1 strains from different geographical areas were used to represent 2007 to 2010 cholera epidemics in Kenya, and were characterized by serotyping, biotyping, polymerase chain r(PCR), pulsed-field gel electrophoresis (PFGE) and ribotyping along with antimicrobial susceptibility testing.

resultsSeventy six Vibrio cholerae O1 strains from different geographical areas were used to represent 2007 to 2010 cholera epidemics in Kenya. Serotype Inaba was dominant (88.2%) compared to Ogawa. The isolates showed varying levels of antibiotic resistance ranging from 100% susceptible to tetracycline, doxycycline, ofloxacin, azithromycin, norfloxacin and ceftriaxone to 100% resistant to furazolidone, trimethoprim-sulfamethoxazole, polymyxin-B and streptomycin. The isolates were positive for ctxA, tcpA (El Tor), rtxC genes and were biotype El Tor variant harboring classical ctxB gene. All the isolates were classified as cholera toxin (CT) genotype 1 as they had mutation in the ctxB at positions 39 and 68. All the isolates had genetically similar NotI PFGE and BglI ribotype patterns. The absence of any observed variation is consistent with a clonal origin for all of the isolates.

conclusionKenya experienced cholera numerous outbreak from 2007-2010. The clinical Vibrio cholerae O1 isolates from the recent cholera epidemic were serotypes Inaba and Ogawa, Inaba being the predominant serotype. The Vibrio cholerae O1 strains were biotype El Tor variants that produce cholera toxin B (ctx B) of the classical type and were positive for ctxA, tcpA El Tor and rtxC genes.

Indexed as

Anti-Bacterial AgentsCholeraCholera ToxinCross-Sectional StudiesDrug Resistance, BacterialElectrophoresis, Gel, Pulsed-FieldGenotypeHumansKenyaMicrobial Sensitivity TestsPolymerase Chain ReactionVibrio cholerae O1Anti-Bacterial AgentsCholera ToxincharacterizationCholeraepidemicsKenyapulsed-field gel electrophoresisserotype

Identifiers

PMID25584121
PMCPMC4286715
OpenAlexW2054938892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.